Learn More
R&D Systems™ Human Lymphotoxin alpha1/beta2, Carrier-Free Recombinant Protein
Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility. Applications: Bioactivity
Brand: R&D Systems™ 8884-LY-025/CF
Description
The Recombinant Human Lymphotoxin alpha1/beta2 Protein is derived from HEK293. The Recombinant Human Lymphotoxin alpha1/beta2 Protein has been validated for the following applications: Bioactivity.Specifications
| 4049 | |
| 25μg | |
| Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70° C as supplied. 1 month, 2 to 8° C under sterile conditions after reconstitution. 3 months, -20 to -70° C under sterile conditions after reconstitution. | |
| Lymphotoxin | |
| Measured by its ability to induce IL-8 secretion by A375 human melanoma cells. The ED50 for this effect is typically 3-15ng/mL. | |
| Yes |
| Observed M.W.: 65-76kDa, reducing conditions, Theoretical M.W.: 61kDa | |
| Human embryonic kidney cell,HEK293-derived human Lymphotoxin protein, (N-terminus) rhLT alpha (Leu35-Leu205) Accession &Num; P01374 GGGGS rhLT beta (Gln49-Gly244) Accession &Num; Q06643 GGGGS rhLT beta (Gln49-Gly244) Accession &Num; Q06643 (C-terminus) | |
| <0.10 EU per 1μg of the protein by the LAL method. | |
| LTA | |
| Unconjugated |
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.